Ventripoint Selected by Life Sciences Ontario as 2021 Success Story
*** LSO Initiates Campaign to Inform Ontario MPPs of Activity within the Sector ***
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Ventripoint will be highlighted as one of Life Sciences Ontario (LSO) 2021 Success Stories (https://lifesciencesontario.ca/reports-and-publications/). The LSO campaign aims to highlight companies and institutions that are creating innovative solutions in the life science sector.
The LSO is a member-funded, non-for-profit organization that works to advance advocacy and policy work, education and networking events, and support services for the life sciences sector. As part of the campaign, Ventripoint’s story will be distributed at LSO Queens Park meetings where MPPs are engaged on future policy development as an example of innovation that improves healthcare in a more cost-effective manner.
“Ontario’s life sciences industry is dedicated to bringing new innovations to improve the lives of all Canadians. Success stories, like Ventripoint Diagnostics, show how scientific discoveries can be turned into real-world solutions; while creating jobs and prosperity here in Ontario,” Dr. Jason Field, CEO, and President of Life Sciences Ontario.
The VMS+ is the first cost effective and accurate system for measuring the function all four chambers of the heart. This initiative will help to bring brand awareness and spread the word about Ventripoint’s innovative solution to improve cardiac diagnosis for everyone worldwide and especially for children.
About Life Sciences Ontario
LSO’s mission is to foster commercial success for Ontario’s life sciences sector through advocacy and education, and promoting the industry locally, nationally, and internationally. The LSO works to increase the profile of Ontario’s Life Sciences sector to secure economic and social prosperity. The organization’s education around successful companies within the sector facilitates will support the growth and development of the life science sector.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
FOR FURTHER INFORMATION CONTACT
Dr. George Adams
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.